JPWO2022047033A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022047033A5 JPWO2022047033A5 JP2023513355A JP2023513355A JPWO2022047033A5 JP WO2022047033 A5 JPWO2022047033 A5 JP WO2022047033A5 JP 2023513355 A JP2023513355 A JP 2023513355A JP 2023513355 A JP2023513355 A JP 2023513355A JP WO2022047033 A5 JPWO2022047033 A5 JP WO2022047033A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- combination
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 241001678559 COVID-19 virus Species 0.000 claims description 17
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 7
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 208000025721 COVID-19 Diseases 0.000 claims description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 230000003115 biocidal effect Effects 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 210000003281 pleural cavity Anatomy 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 206010060964 Arterial haemorrhage Diseases 0.000 claims description 2
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- 208000020446 Cardiac disease Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 201000006306 Cor pulmonale Diseases 0.000 claims description 2
- 208000005189 Embolism Diseases 0.000 claims description 2
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 229940125583 Inovio COVID-19 vaccine Drugs 0.000 claims description 2
- 206010024971 Lower respiratory tract infections Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 229940026232 Novavax COVID-19 vaccine Drugs 0.000 claims description 2
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 claims description 2
- 206010030113 Oedema Diseases 0.000 claims description 2
- 206010035603 Pleural mesothelioma Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 229940025291 Sinovac-CoronaVac COVID-19 vaccine Drugs 0.000 claims description 2
- 102220590621 Spindlin-1_T19R_mutation Human genes 0.000 claims description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003805 amantadine Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 208000037849 arterial hypertension Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- 229940052143 bamlanivimab Drugs 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 229940051183 casirivimab Drugs 0.000 claims description 2
- 229960003677 chloroquine Drugs 0.000 claims description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 229940051243 etesevimab Drugs 0.000 claims description 2
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims description 2
- 229950008454 favipiravir Drugs 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- 208000018578 heart valve disease Diseases 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 229940051184 imdevimab Drugs 0.000 claims description 2
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 208000037841 lung tumor Diseases 0.000 claims description 2
- 229940023146 nucleic acid vaccine Drugs 0.000 claims description 2
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- PGZUMBJQJWIWGJ-ONAKXNSWSA-N oseltamivir phosphate Chemical compound OP(O)(O)=O.CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 PGZUMBJQJWIWGJ-ONAKXNSWSA-N 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 claims description 2
- 229960000471 pleconaril Drugs 0.000 claims description 2
- 201000003144 pneumothorax Diseases 0.000 claims description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 2
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 2
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 2
- 229960000888 rimantadine Drugs 0.000 claims description 2
- 229940061367 tamiflu Drugs 0.000 claims description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 claims 7
- 101710114810 Glycoprotein Proteins 0.000 claims 2
- 101710167605 Spike glycoprotein Proteins 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 description 64
- 108090000765 processed proteins & peptides Proteins 0.000 description 64
- 102000004196 processed proteins & peptides Human genes 0.000 description 64
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 18
- 108010032595 Antibody Binding Sites Proteins 0.000 description 6
- 241000288906 Primates Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 102000048657 human ACE2 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070707P | 2020-08-26 | 2020-08-26 | |
| US63/070,707 | 2020-08-26 | ||
| PCT/US2021/047757 WO2022047033A1 (en) | 2020-08-26 | 2021-08-26 | Antigen binding molecules targeting sars-cov-2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540037A JP2023540037A (ja) | 2023-09-21 |
| JPWO2022047033A5 true JPWO2022047033A5 (https=) | 2024-08-26 |
| JP2023540037A5 JP2023540037A5 (https=) | 2024-08-26 |
Family
ID=77897739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513355A Pending JP2023540037A (ja) | 2020-08-26 | 2021-08-26 | ＳＡＲＳ－ＣｏＶ－２を標的にする抗原結合分子 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11987616B2 (https=) |
| EP (1) | EP4204446A1 (https=) |
| JP (1) | JP2023540037A (https=) |
| KR (1) | KR20230058434A (https=) |
| CN (1) | CN116528897A (https=) |
| AU (1) | AU2021332340A1 (https=) |
| CA (1) | CA3188716A1 (https=) |
| IL (1) | IL300720A (https=) |
| WO (1) | WO2022047033A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299631A (en) | 2020-07-06 | 2023-03-01 | Flagship Pioneering Innovations Vi Llc | Antigen binding molecules targeting sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| AR123469A1 (es) * | 2020-09-10 | 2022-12-07 | Bighat Biosciences Inc | DOMINIOS DE UNIÓN A LA GLICOPROTEÍNA ESPICULAR DEL SARS-CoV(-2) Y POLIPÉPTIDOS QUE LOS COMPRENDEN Y USO DE ESTOS |
| AU2023265164A1 (en) | 2022-05-06 | 2024-11-21 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
| JP2025537301A (ja) | 2022-11-13 | 2025-11-14 | ジェネレイト バイオメディシンズ， インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２を標的とする抗原結合分子 |
| CN117442594A (zh) * | 2023-04-20 | 2024-01-26 | 厦门大学 | 化合物在诊断与治疗新型冠状病毒感染中的应用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2531684C (en) | 2003-07-22 | 2014-03-11 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| CA2548942C (en) | 2003-12-05 | 2013-10-15 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Anti-sars monoclonal antibodies |
| EP1812067B1 (en) | 2004-11-11 | 2012-03-21 | Crucell Holland B.V. | Compositions against sars-coronavirus and uses thereof |
| DK1817340T3 (da) | 2004-11-12 | 2012-08-13 | Xencor Inc | Fc-varianter med ændret binding til fcrn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| RU2529951C2 (ru) | 2007-12-26 | 2014-10-10 | Ксенкор, Инк. | ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn |
| PT3031913T (pt) | 2013-08-09 | 2019-05-31 | Astellas Pharma Inc | Novo anticorpo anti-receptor de tslp humana |
| CA2962731A1 (en) | 2014-10-01 | 2016-04-07 | Medimmune Limited | Binding proteins specific for lox1 and uses thereof |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| JP7695698B2 (ja) | 2019-01-14 | 2025-06-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 細胞内部移行をモジュレートするための組成物および方法 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
| JP2023512684A (ja) | 2020-02-03 | 2023-03-28 | ヴィア・バイオテクノロジー・インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法 |
| WO2021156490A2 (en) * | 2020-02-06 | 2021-08-12 | Vib Vzw | Corona virus binders |
| SG11202110145SA (en) | 2020-02-26 | 2021-10-28 | Vir Biotechnology Inc | Antibodies against sars-cov-2 and methods of using the same |
| CN115515976A (zh) | 2020-03-19 | 2022-12-23 | 帝国理工学院创新有限公司 | 冠状病毒抗体 |
| US11028167B1 (en) | 2020-03-23 | 2021-06-08 | Centivax, Inc. | Anti-SARS-Cov-2 antibodies derived from 3bgf |
| CR20220552A (es) | 2020-04-02 | 2023-01-17 | Regeneron Pharma | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno |
| WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
| US20230348571A1 (en) | 2020-04-06 | 2023-11-02 | Vanderbilt University | Cross-reactive coronavirus antibodies and uses thereof |
| TW202204397A (zh) | 2020-04-10 | 2022-02-01 | 美商亞得捷歐治療公司 | 對冠狀病毒s蛋白質具特異性之化合物及其用途 |
| JP2023523549A (ja) | 2020-04-14 | 2023-06-06 | ヴィア・バイオテクノロジー・インコーポレイテッド | ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法 |
| CN115461364B (zh) | 2020-04-28 | 2025-12-16 | 北京大学 | 一种抗新型冠状病毒的单克隆抗体及其应用 |
| MX2022013886A (es) | 2020-05-08 | 2022-11-30 | Vir Biotechnology Inc | Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2). |
| WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| IL299631A (en) | 2020-07-06 | 2023-03-01 | Flagship Pioneering Innovations Vi Llc | Antigen binding molecules targeting sars-cov-2 |
| WO2022015573A2 (en) | 2020-07-13 | 2022-01-20 | President And Fellows Of Harvard College | Sars-cov-2 antigen-binding proteins and uses thereof |
| EP4188951A4 (en) | 2020-07-27 | 2024-08-28 | IGM Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022046888A1 (en) | 2020-08-25 | 2022-03-03 | Target Discovery Merger Sub II, LLC | Sars-cov-2 associated antibody compositions and methods of use |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| JP2024502046A (ja) | 2020-12-29 | 2024-01-17 | バル－チャム，リミティド パートナーシップ | Ｃｏｖｉｄ－１９に対する中和モノクローナル抗体 |
| WO2022159685A2 (en) | 2021-01-22 | 2022-07-28 | Vanderbilt University | Sars-cov-2 coronavirus antibodies and uses thereof |
| WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| CA3218489A1 (en) | 2021-05-24 | 2022-12-01 | Vir Biotechnology, Inc. | Engineered polypeptides |
| US20240270797A1 (en) | 2021-06-23 | 2024-08-15 | Cz Biohub Sf, Llc | Coronavirus neutralizing compositions and associated methods |
| TW202315895A (zh) | 2021-08-27 | 2023-04-16 | 瑞士商休曼生物醫藥股份公司 | 經工程化的組成物 |
| EP4147716A1 (en) | 2021-09-10 | 2023-03-15 | Samatva Research Corporation | Anti-virus moiety immobilised in a matrix |
| AU2023265164A1 (en) | 2022-05-06 | 2024-11-21 | Generate Biomedicines, Inc. | Antigen binding molecules targeting sars-cov-2 |
-
2021
- 2021-08-26 KR KR1020237009720A patent/KR20230058434A/ko active Pending
- 2021-08-26 CA CA3188716A patent/CA3188716A1/en active Pending
- 2021-08-26 WO PCT/US2021/047757 patent/WO2022047033A1/en not_active Ceased
- 2021-08-26 AU AU2021332340A patent/AU2021332340A1/en active Pending
- 2021-08-26 CN CN202180052278.1A patent/CN116528897A/zh active Pending
- 2021-08-26 IL IL300720A patent/IL300720A/en unknown
- 2021-08-26 EP EP21773945.7A patent/EP4204446A1/en active Pending
- 2021-08-26 JP JP2023513355A patent/JP2023540037A/ja active Pending
-
2023
- 2023-02-15 US US18/169,464 patent/US11987616B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090068181A1 (en) | Bispecific antibodies | |
| US11981725B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
| JP2010518854A5 (https=) | ||
| US11987616B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
| CN110678196B (zh) | 抗hekr-k包膜抗体及其用途 | |
| WO2022083675A1 (zh) | 针对多种冠状病毒的单克隆抗体及应用 | |
| JP2023528826A (ja) | Ｓａｒｓ関連コロナウイルスに対する中和抗体 | |
| JP2023534922A (ja) | ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子 | |
| JPWO2018070390A1 (ja) | 抗ｒｏｂｏ４抗体と他剤を含む組成物 | |
| WO2021212785A1 (zh) | 一种全人源单克隆抗体及其应用 | |
| CN109983030A (zh) | cMET单克隆结合剂、其药物缀合物及其用途 | |
| JPWO2022047033A5 (https=) | ||
| JPWO2022010921A5 (https=) | ||
| JPWO2022010912A5 (https=) | ||
| WO2023148641A1 (en) | Monoclonal antibodies specific to receptor binding domain of sars-cov2 and uses thereof | |
| CN118076641A (zh) | 抗cd26抗体及其应用 | |
| WO2022023292A2 (en) | Corona virus spike protein-targeting antibodies and use thereof | |
| CN119638829B (zh) | 抗pspb抗体及其应用 | |
| US20220289827A1 (en) | Neutralizing antibodies to sars-cov-2 and its variants | |
| CN116635410A (zh) | 靶向SARS-CoV-2的抗原结合分子 | |
| WO2025177283A1 (en) | Antibody-drug conjugates for targeting fibrosis | |
| US20240043506A1 (en) | Sars-cov-2 antibodies | |
| CN116547005A (zh) | 靶向SARS-CoV-2的抗原结合分子 | |
| CN121426940A (zh) | 特异性结合呼吸道合胞病毒的抗体及其应用 | |
| CN119923414A (zh) | 溶酶体降解 |